After 4.5 years, XZK was associated with a highly significant reduction in frequency of coronary events (10.4% in the placebo vs 5.7% in the XZK group) and a relative risk reduction of 45% [ 189 ].
← all excerpts
The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway.
1
—
—